Why These 15 Healthcare Stocks Are Surging in 2025

Page 7 of 14

8. Chimerix Inc (NASDAQ:CMRX)

Number of Hedge Fund Holders In Q4 2024: 17

Chimerix Inc (NASDAQ:CMRX) is a biopharmaceutical company focused on developing medicines for deadly diseases, with its lead candidate dordaviprone targeting recurrent H3 K27M-mutant diffuse glioma, a rare brain cancer.

The stock’s dramatic rise in 2025, at one point up nearly 70% in a single day, was primarily triggered by two major events.

The first was the March 2025 announcement that the FDA accepted Chimerix’s New Drug Application for dordaviprone and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) decision date set for August 18, 2025.

The second, and even more significant, event was the March 5, 2025 announcement that Jazz Pharmaceuticals would acquire Chimerix for $8.55 per share in cash, valuing the deal at about $935 million. This acquisition news caused Chimerix shares to surge.

The consensus price target of $8.53 implies 0.08% downside.

CMRX stock is up 145.40% year-to-date.

Page 7 of 14